Palvella expands QTORIN rapamycin development to angiokeratomas
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin’s Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved The
September 24, 2025 6:00 AM EDTClinically significant angiokeratomas are characterized by lymphatic-derived skin lesions that can persistently bleed and significantly impact quality-of-life; no FDA-approved therapies exist for the estimated more than 50,000 diagnosed U.S. patients
Company plans to initiate a Phase 2 trial evaluating QTORIN rapamycin for clinically significant angiokeratomas in the second half of 2026
Company to host webcast conference call today, September 24, 2025 at 8:30am ET
WAYNE, Pa., Sept. 24, 2025 (GLOBE NEWSWIRE) -- (Nasdaq:... More
